A Phase 3 Open-label Clinical Study of Doravirine/Islatravir (DOR/ISL [100 mg/0.25 mg]) Once Daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL (100 mg/0.75 mg) QD in a Phase 3 Clinical Study
A Phase 3 Open-label Clinical Study of Doravirine/Islatravir (DOR/ISL [100 mg/0.25 mg]) Once Daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL (100 mg/0.75 mg) QD in a Phase 3 Clinical Study
The purpose of this study is to evaluate the safety and tolerability of DOR/ISL in adult participants with HIV-1 who had been previously treated with DOR/ISL in earlier clinical studies. There are no formal hypotheses to be tested in this study.
Inclusion Criteria:
Exclusion Criteria:
Birmingham, Alabama 35222, United States
Sacramento, California 95817, United States
Washington D.C., District of Columbia 20007, United States
Macon, Georgia 31201, United States
Savannah, Georgia 31401, United States
New York, New York 10029, United States
Philadelphia, Pennsylvania 19104, United States
Spokane, Washington 99202, United States
Temuco, Araucania 4781151, Chile
Santiago, Region M. de Santiago 8380420, Chile
Bogotá, Bogota D.C. 111321, Colombia
Haifa, 3109601, Israel
Bunkyo, Tokyo 113-8677, Japan
Shinjuku-ku, Tokyo 160-0023, Japan
Shinjyuku-ku, Tokyo 162-8655, Japan
Osaka, 540-0006, Japan
Kemerovo, Kemerovo Oblast 650056, Russia
Krasnoyarsk, Krasnoyarsk Krai 660049, Russia
Saint Petersburg, Leningradskaya Oblast' 196645, Russia
Moscow, Moscow 115035, Russia
Saint Petersburg, Sankt-Peterburg 190020, Russia
Kazan', Tatarstan, Respublika 420140, Russia
Johannesburg, Gauteng 2013, South Africa
Johannesburg, Gauteng 2092, South Africa
Cape Town, Western Cape 7505, South Africa
Geneva, Canton of Geneva 1211, Switzerland
Lugano, Canton Ticino 6903, Switzerland
East Sussex, Brighton And Hove BN2 1ES, United Kingdom